4887.T Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 апр. 2024 @ 09:15):

Stats
Объем за сегодня	147 300
Средний объем	251 433
Рыночная капитализация	260.93B
EPS	¥0 ( 2024-02-13 )
Дата следующего отчета о доходах	( ¥59.41 ) 2024-05-08
Last Dividend	¥65.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	19.76
ATR14	¥3.48 (0.06%)

Объем Корреляция

Длинно: -0.10 (neutral)

Кратко: 0.12 (neutral)

Signal:(63.551) Neutral

Sawai Group Holdings Co., Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Sawai Group Holdings Co., Корреляция - Валюта/Сырье

-0.70
( moderate negative )

-0.47
( neutral )

-0.23
( neutral )

-0.60
( weak negative )

0.25
( neutral )

-0.13
( neutral )

Sawai Group Holdings Co., Финансовые показатели

Annual	2022
Выручка:	¥200.34B
Валовая прибыль:	¥62.63B (31.26 %)
EPS:	¥289.26

FY	2022
Выручка:	¥200.34B
Валовая прибыль:	¥62.63B (31.26 %)
EPS:	¥289.26

FY	2022
Выручка:	¥193.82B
Валовая прибыль:	¥66.65B (34.39 %)
EPS:	¥-957.37

Financial Reports:

No articles found.

Sawai Group Holdings Co., Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥65.00 (N/A)	¥0 (N/A)	¥65.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Sawai Group Holdings Co., Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 9.15 - good (91.49%) | Divividend Growth Potential Score: 4.60 - Stable (8.03%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥65.00	2021-09-29
Last Dividend	¥65.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	5	--
Total Paid Out	¥260.00	--
Avg. Dividend % Per Year	0.00%	--
Score	3.11	--
Div. Sustainability Score	9.15
Div.Growth Potential Score	4.60
Div. Directional Score	6.87	--

Next Divdend (Est)
(2024-07-03)

¥0 Estimate 0.00 %

Dividend Stability

0.09 Very Bad

Dividend Score

3.11

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8362.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
7743.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
6925.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
6284.T	Ex Dividend Knight	2023-09-28	Annually	0.00%
4998.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
4206.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
3407.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
2497.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
9434.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
8086.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0749	1.500	8.50	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0392	1.200	8.69	10.00	[0 - 0.3]
returnOnEquityTTM	0.0735	1.500	-0.294	-0.441	[0.1 - 1]
payoutRatioTTM	0.372	-1.000	6.28	-6.28	[0 - 1]
currentRatioTTM	2.18	0.800	4.09	3.27	[1 - 3]
quickRatioTTM	0.782	0.800	-0.108	-0.0867	[0.8 - 2.5]
cashRatioTTM	0.254	1.500	9.70	10.00	[0.2 - 2]
debtRatioTTM	0.229	-1.500	6.19	-9.28	[0 - 0.6]
interestCoverageTTM	40.11	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	544.46	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	-35.66	2.00	-10.00	-10.00	[0 - 20]
debtEquityRatioTTM	0.425	-1.500	8.30	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.305	1.000	8.25	8.25	[0.2 - 0.8]
operatingProfitMarginTTM	0.0968	1.000	-0.0640	-0.0640	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.267	1.000	9.63	9.63	[0.2 - 2]
assetTurnoverTTM	0.524	0.800	9.84	7.87	[0.5 - 2]
Total Score				9.15

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	17.03	1.000	8.38	0	[1 - 100]
returnOnEquityTTM	0.0735	2.50	-0.189	-0.441	[0.1 - 1.5]
freeCashFlowPerShareTTM	-35.66	2.00	-10.00	-10.00	[0 - 30]
dividendYielPercentageTTM	2.18	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	544.46	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.372	1.500	6.28	-6.28	[0 - 1]
pegRatioTTM	1.094	1.500	6.04	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.117	1.000	9.59	0	[0.1 - 0.5]
Total Score				4.60

Sawai Group Holdings Co.,

Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research, development, manufacturing, and marketing of generic pharmaceutical products primarily in Japan and the United States. It offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, capsules, granules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms in the therapeutic areas of cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, urogenital organs and the anus, antineoplastic, vitamins, anti-cancer, chemotherapeutic agents, respiratory organ agents, hormone agents, etc. The company's products include atorvastatin, limaprost alfadex, lansoprazole, aprepitant, micafungin sodium, silodosin, blonanserin, oseltamivir, capecitabine, atomoxetine hydrochloride, nalfurafine, memantine hydrochloride, eldecalcitol, bazedoxifene, fexofenadine hydrochloride, dutasteride, pregabalin, duloxetine hydrochloride, morphine sulfate tablets, tosymra nasal spray, zembrace symtouch, and ramelteon tablets. It also manufactures and sells medicinal products. The company sells its generic drugs to distributors, retail stores, and other pharmaceutical manufacturers, as well as directly to medical institutions, such as hospitals, general practitioners, and dispensing pharmacies in Japan; and pharmaceutical products to wholesalers in the United States. Sawai Group Holdings Co., Ltd. was founded in 1929 and is headquartered in Osaka, Japan.